Literature DB >> 11095813

Antibiotic Selection for Urinary Tract Infection: New Microbiologic Considerations.

.   

Abstract

Urinary tract infection (UTI) is an extremely common clinical condition, especially among women, half of whom will have at least one episode of acute cystitis at some point during adult life. An estimated one quarter of these women will have frequent, recurrent UTI. The microbiology of uncomplicated UTI is very predictable, with the vast majority of cases attributed to Escherichia coli. Recent reports from the United States and Europe have shown that resistance among uropathogens to agents that have traditionally been recommended as firstline therapy for uncomplicated UTI is on the rise. Although resistance to fluoroquinolone antibiotics among community-acquired uropathogens remains very low in the United States, fluoroquinolone resistance in community-acquired UTI isolates from other parts of the world has been increasingly described. Very low levels of resistance to nitrofurantoin among uropathogens has revived interest in this agent. The effect of in vitro resistance in uropathogens on the clinical response to treatment of acute cystitis is not well studied. The implications of emerging resistance among the causative agents of this extremely common infection for therapy of UTI are discussed.

Entities:  

Year:  1999        PMID: 11095813     DOI: 10.1007/s11908-999-0046-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  27 in total

1.  Recurrent urinary tract infection: new theories and old remedy.

Authors:  D A Cramer
Journal:  Ann Intern Med       Date:  1998-02-15       Impact factor: 25.391

Review 2.  Prevention of urinary tract infection.

Authors:  A Stapleton; W E Stamm
Journal:  Infect Dis Clin North Am       Date:  1997-09       Impact factor: 5.982

Review 3.  Diagnosis and treatment of uncomplicated urinary tract infection.

Authors:  T M Hooton; W E Stamm
Journal:  Infect Dis Clin North Am       Date:  1997-09       Impact factor: 5.982

Review 4.  Management of urinary tract infections in adults.

Authors:  W E Stamm; T M Hooton
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

5.  Urinary tract infections in females.

Authors:  C M Kunin
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

6.  Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

7.  Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women.

Authors:  K Gupta; D Scholes; W E Stamm
Journal:  JAMA       Date:  1999-02-24       Impact factor: 56.272

8.  The effectiveness of a clinical practice guideline for the management of presumed uncomplicated urinary tract infection in women.

Authors:  S Saint; D Scholes; S D Fihn; R G Farrell; W E Stamm
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

9.  Which bacteria are found in Belgian women with uncomplicated urinary tract infections in primary health care, and what is their susceptibility pattern anno 95-96?

Authors:  T H Christiaens; S Heytens; G Verschraegen; M De Meyere; J De Maeseneer
Journal:  Acta Clin Belg       Date:  1998-06       Impact factor: 1.264

10.  Recurring urinary tract infection: incidence and risk factors.

Authors:  B Foxman
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

View more
  2 in total

Review 1.  Recurrent urinary tract infection in women: emerging concepts regarding etiology and treatment considerations.

Authors:  E Ann Gormley
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

2.  Impact of Changing Patterns of Antimicrobial Resistance in Uropathogens: Emerging Treatment and Strategies.

Authors:  Patricia D. Brown
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.